Every 8-K that PETROS PHARM INC (PTPI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PTPI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTPI filings page.
Petros Pharmaceuticals, Inc. reported a leadership change in its finance organization. The company and Mitchell Arnold, its Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to his separation effective June 18, 2026, under a General Release and Severance Agreement.
The agreement provides a severance payment of $38,500, acceleration of 3,000 unvested restricted shares, a $100 cash payment related to taxes on equity awards, and up to two months of COBRA premium payments if he elects continued coverage. In exchange, Arnold grants a broad release of claims.
On the same date, the board appointed Robert Weinstein as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately. Weinstein brings more than thirty years of accounting and finance experience, including prior public-company CFO roles and board positions in the biotechnology and healthcare sectors.
Petros Pharmaceuticals, Inc. approved new equity awards for key leaders. On June 5, 2026, the Board granted an aggregate of 7,000,000 restricted shares of common stock to its chairman, two directors, and its President and Chief Commercial Officer. Joshua Silverman received 4,375,000 restricted shares, Bruce Bernstein 1,875,000, and both Fady Boctor and Wayne Walker 375,000 each. Half of each award vested immediately on the grant date, and the remaining half will vest six months later if the recipient is still providing services. These restricted share awards were issued outside the company’s Amended and Restated 2020 Omnibus Incentive Compensation Plan and are governed by a standard Restricted Stock Award Agreement.
Petros Pharmaceuticals, Inc. reported that its Board of Directors approved new equity awards for key directors and an executive officer. Effective January 2, 2026, the company granted a total of 7,250,000 restricted stock units (RSUs), including 4,375,000 RSUs to Chairman Joshua Silverman, 1,875,000 RSUs to director Bruce Bernstein, 500,000 RSUs to President and Chief Commercial Officer Fady Boctor, and 500,000 RSUs to director Wayne Walker. Each RSU gives the holder the right to receive one share of Petros common stock. Half of each grant vested on the grant date, with the remaining half scheduled to vest six months later, as long as the recipient continues providing services to the company. These RSU awards were issued outside the company’s 2020 Omnibus Incentive Compensation Plan and are governed by Petros’s standard Restricted Stock Unit Agreement.
Petros Pharmaceuticals (PTPI) reported a Nasdaq delisting process. Nasdaq notified the company on November 3, 2025 that it intends to announce the delisting of Petros’ common stock. Nasdaq will file a Form 25 to deregister the stock under Section 12(b), and the delisting becomes effective ten days after that filing.
The stock was suspended from The Nasdaq Capital Market on May 22, 2025 and has traded on the OTCID Basic Market under “PTPI” since July 1, 2025. Petros states trading on the OTCID will continue without disruption, and the company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.